Key Highlights

  • 1.01 USD is the consensus loss per share (an EPS estimate of -1.01) for Helus Pharma (NASDAQ:HELP) ahead of its November 13, 2026 report, which is flagged for before the market opens.
  • 166.4 million USD is the cash reported at June 30, 2026, while the net loss for that quarter was 47.8 million USD, against 24.6 million USD in the prior-year quarter.
  • 37.5 million USD is the cash-based Operating Expense reported for the quarter ended June 30, 2026, versus 23.9 million USD a year earlier, with 37.1 million USD of cash used in operations.
  • 686.12 million USD is the market Capitalization per the screener snapshot, and topline data from the Phase 3 APPROACH study is expected in the fourth quarter of 2026.

What Investors Expect From Helus Pharma (NASDAQ:HELP) on November 13, 2026

Per the screener snapshot, Helus Pharma, formerly Cybin, reports fiscal second quarter 2027 results on November 13, 2026, before the market opens, with a consensus EPS estimate of -1.01 and a market capitalization of USD 686.12 million. The quarter covers the three months to September 30, 2026, and the fiscal year ends March 31. For the prior-year comparison, the company reported a net loss of USD 33.7 million for the quarter ended September 30, 2025, with cash of USD 83.8 million and cash-based operating expenses of USD 28.5 million.

The Rationale: Last Reported Quarter and Management Outlook for Helus Pharma (NASDAQ:HELP)

In the fiscal first quarter 2027, ended June 30, 2026, the company reported a net loss of USD 47.8 million versus USD 24.6 million, with operating expenses of USD 37.5 million versus USD 23.9 million and operating cash use of USD 37.1 million versus USD 29.5 million. Cash was USD 166.4 million, helped by a USD 50 million underwritten offering in June 2026. Enrollment in the Phase 3 APPROACH study in major depressive disorder is complete, with topline data expected in the fourth quarter of 2026. The EMBRACE study is enrolling, the next anxiety study design is due by the end of the third quarter of 2026, and a development candidate for HLP005 is anticipated in the second half of 2027.

Valuation, Liquidity and Risks for Helus Pharma (NASDAQ:HELP)

The Market Value is USD 686.12 million per the screener snapshot. The company launched a USD 100 million at-the-market Equity program in December 2025, which could add dilution. EPS, total debt, share count and a cash runway estimate were not found in the first quarter release. Phase 2 data cited by the company include a MADRS reduction of about 23 points at 12 months for HLP003 and a 10-point improvement on the Hamilton Anxiety scale for HLP004. Risks include trial outcomes, regulatory review, financing needs and the company note that there is no assurance that timelines will be met.

Where Things Stand

Where things stand: Helus Pharma (NASDAQ:HELP) reports with a consensus EPS estimate of -1.01, a market capitalization of USD 686.12 million and USD 166.4 million of cash at June 30, 2026. The net loss of USD 47.8 million in the prior quarter was nearly double the USD 24.6 million a year earlier (calculated at about 1.9 times). Management points to topline APPROACH data in the fourth quarter of 2026, which makes the quarter a bridge between spending and a binary clinical event. Investors will watch burn, financing activity and any update on timelines. The company has no revenue, and the release gives no numerical financial guidance. This is information only and not Investment advice.